Full-Time

Territory Representative

SI-BONE

SI-BONE

501-1,000 employees

Minimally invasive sacroiliac joint implant provider

Compensation Overview

$60k - $80k/yr

+ Monthly variable pay + Stock

Waterbury, CT, USA

In Person

Territory includes Connecticut and Western Massachusetts; significant travel within territory required.

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Inventory Management

Get referred to SI-BONE

See people who can refer or advise you

Requirements
  • Bachelor’s Degree in Marketing, Finance, Business or equivalent discipline.
  • Currently or recently served in a sales position of a high-growth, medical device or pharmaceutical organization whose products are marketed to a medical specialty practice and worked in a leadership capacity for a minimum of 3 years.
  • Knowledge and familiarity of applicable regulations/standards (e.g. ISO 13485, FDA 21 CFR 820, EU MDR 2017/745, ISO 14971) as required to perform the job function.
Responsibilities
  • Establish rapport and a solid working relationship with surgeon customers as well as with all employees.
  • Assist Territory Manager and Region in meeting or exceeding quota on a consistent basis.
  • Manage all travel and entertainment expenses consistent with company policy and within regional budget guidelines.
  • Establish and manage referral channel networks; utilize integrated marketing information, high prescriber lists, and other leads to identify physicians and patients interested in SI joint treatment options.
  • Work closely with sales management to identify, execute and support educational activities within the territory to ensure maximum awareness of the SI joint as a pain generator and establish solid referral patterns to trained iFuse surgeons.
  • Provide the necessary reporting materials and communicate effectively and openly to the Territory Manager and Sales Management Team as required.
  • Responsible for management of implant shelf life and instrument sets provided to them. Damaged or expired product to be returned to SI-BONE, Inc.
  • Support the SI-Bone Quality System.
  • Reports to the hiring Regional Sales Director and has responsibility for managing specified territory as determined by senior management.
Desired Qualifications
  • Experience in orthopedics or pain management is desired.
  • Spine experience also a plus.
  • Strong relationships with local physician groups, including primary care, pain management, orthopedic and neurosurgery.
  • A demonstrated ability to communicate effectively and work well with sales management.
  • Results oriented and customer focused.
  • Demonstrated adaptability and initiative.
  • A demonstrated history of successfully achieving goals, objectives and high performance.
  • A positive, self-confident and decisive work ethic with excellent communication skills in both oral and written formats, as well as excellent listening skills.
  • A proactive approach to attacking problems and identifying solutions, displaying initiative and perseverance in order to bring about meaningful change and is open and responsive to new ideas.
  • Be known as a person who has high integrity, sound character, a tremendous work ethic and the passion to succeed.

SI-BONE focuses on treating sacroiliac joint dysfunction, a common source of lower back pain, by offering a minimally invasive implant system called iFuse. The iFuse Implant System is implanted surgically to stabilize the sacroiliac joint with a less invasive approach that aims for quicker recovery compared to traditional methods. The company gained FDA clearance for this implant, validating its use in patients. In 2018, SI-BONE went public on the NASDAQ, providing capital to expand research, development, and market presence. Its ongoing goal is to improve patient outcomes through education and continued development of sacroiliac joint treatments. Unlike broader orthopedic device makers, SI-BONE specializes in a targeted SI joint solution and builds its business around a single reusable implant technology and related surgical tools.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Jose, California

Founded

2008

Get referred to SI-BONE

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 15.2% to $56.0 million, lifting 2026 guidance.
  • Adjusted EBITDA turned positive at $2.8 million in Q2 2026.
  • European and Australian launches expanded international revenue 25.9% in Q2 2026.

What critics are saying

  • Medtronic, Globus, and Orthofix pressure SI-BONE with broader spine bundles.
  • NTAP and reimbursement advantages expire in 2027-2028, compressing margins after October 1, 2026.
  • SI-BONE remains unprofitable; Q2 2026 net loss was $4.1 million.

What makes SI-BONE unique

  • iFuse Bedrock Granite won CMS higher inpatient payments effective October 1, 2026.
  • SI-BONE grew active U.S. physicians 17% to 1,715 by Q2 2026.
  • iFuse TORQ TNT and TORQ extend SI-BONE into pelvic trauma globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
Yahoo Finance
Aug 3rd, 2026
SI-BONE reports 15% revenue growth to $56M, swings to positive adjusted EBITDA of $2.8M

SI-BONE reported second quarter 2026 worldwide revenue of $56.0 million, up 15.2% year-over-year. US revenue reached $53.2 million, growing 14.7%, driven by 14.9% procedure volume growth. International revenue was $2.8 million, up 25.9%. The medical device company achieved gross margin of 79.5% and positive adjusted EBITDA of $2.8 million, improving 178% year-over-year. Net loss was $4.1 million, a 33.6% improvement. Cash from operations turned positive at $0.8 million. The company's active US physician base grew 19% to 1,715. SI-BONE submitted a 510(k) application in June for its third breakthrough device targeting spine surgery needs. The Centers for Medicare & Medicaid Services finalised higher payment rates for complex spinal fusion procedures using iFuse Bedrock Granite, effective 1 October. SI-BONE raised its 2026 guidance following the results.

MarketBeat
Jul 28th, 2026
SiBone (NASDAQ:SIBN) shares gap up - still a Buy?

SiBone (NASDAQ:SIBN) shares gap up - still a Buy? July 28, 2026 Key points. * SiBone shares rose 4.8%, opening at $17.72 versus a prior close of $17.05 and last trading near $17.74. * Analyst sentiment remains favorable, with seven Buy ratings and one Sell rating producing a consensus "Moderate Buy" rating and a $23.57 target price. UBS initiated coverage with a Buy rating and a $24 target. * SiBone's latest quarterly results exceeded expectations, reporting an adjusted loss of $0.10 per share versus the $0.17 forecast and revenue of $52.59 million. However, the company remains unprofitable, while institutional investors own 98.11% of its shares and insiders have recently sold stock. * MarketBeat previews top five stocks to own in August. SiBone (NASDAQ:SIBN - Get Free Report) shares gapped up prior to trading on Tuesday. The stock had previously closed at $17.05, but opened at $17.72. SiBone shares last traded at $17.7410, with a volume of 252,650 shares. Wall Street Analyst weigh in. SIBN has been the subject of a number of recent research reports. UBS Group initiated coverage on shares of SiBone in a research note on Tuesday. They issued a "buy" rating and a $24.00 price objective for the company. Wall Street Zen lowered SiBone from a "buy" rating to a "hold" rating in a report on Saturday, April 18th. Truist Financial lifted their price target on SiBone from $18.00 to $21.00 and gave the company a "buy" rating in a research report on Thursday, July 16th. TD Cowen decreased their price objective on SiBone from $22.00 to $18.00 and set a "buy" rating on the stock in a research note on Tuesday, May 12th. Finally, Weiss Ratings raised SiBone from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, July 21st. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $23.57. SiBone trading up 4.8%. The firm's 50 day moving average is $15.97 and its 200 day moving average is $15.18. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.99 and a quick ratio of 8.34. The company has a market cap of $792.07 million, a PE ratio of -45.95 and a beta of 0.67. SiBone (NASDAQ:SIBN - Get Free Report) last posted its earnings results on Monday, May 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.07. The business had revenue of $52.59 million for the quarter, compared to analysts' expectations of $51.16 million. SiBone had a negative net margin of 8.10% and a negative return on equity of 9.56%. On average, equities analysts anticipate that SiBone will post -0.44 earnings per share for the current year. Insider buying and selling. In other SiBone news, SVP Michael A. Pisetsky sold 3,134 shares of the company's stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $16.71, for a total value of $52,369.14. Following the transaction, the senior vice president directly owned 277,375 shares in the company, valued at $4,634,936.25. This represents a 1.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Timothy E. Davis, Jr. sold 3,500 shares of the company's stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $14.14, for a total value of $49,490.00. Following the completion of the transaction, the director owned 65,722 shares in the company, valued at $929,309.08. This represents a 5.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 36,326 shares of company stock valued at $545,661 in the last ninety days. 4.00% of the stock is owned by insiders. Institutional trading of SiBone. Large investors have recently modified their holdings of the business. First Light Asset Management LLC increased its position in shares of SiBone by 162.4% in the fourth quarter. First Light Asset Management LLC now owns 5,032,904 shares of the company's stock worth $99,249,000 after purchasing an additional 3,115,001 shares during the last quarter. Granahan Investment Management LLC grew its stake in SiBone by 97.6% in the 1st quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company's stock worth $21,965,000 after buying an additional 858,942 shares in the last quarter. Paradigm Capital Management Inc. NY grew its stake in SiBone by 113.3% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company's stock worth $14,228,000 after buying an additional 598,300 shares in the last quarter. Cadian Capital Management LP increased its holdings in shares of SiBone by 96.8% in the 4th quarter. Cadian Capital Management LP now owns 1,171,100 shares of the company's stock worth $23,094,000 after buying an additional 576,100 shares during the last quarter. Finally, Wellington Management Group LLP increased its holdings in shares of SiBone by 74.7% in the 3rd quarter. Wellington Management Group LLP now owns 853,266 shares of the company's stock worth $12,560,000 after buying an additional 364,897 shares during the last quarter. Institutional investors own 98.11% of the company's stock. SiBone company profile. Si-BONE, Inc is a commercial-stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain. FDA-cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider SiBone, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SiBone wasn't on the list. While SiBone currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The space race is growing fast, and you don't have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Yahoo Finance
May 12th, 2026
SI-BONE posts $52.6M revenue with 11% growth, improves adjusted EBITDA by 440%

SI-BONE, a medical device company developing solutions for compromised bone, reported first quarter 2026 revenue of $52.6 million, up 11.2% year-over-year. US revenue grew 10.0% to $49.3 million, whilst international revenue surged 33.9% to $3.3 million, driven by demand for iFuse TORQ. The company achieved gross margin of 79.8% and narrowed its net loss by 33.8% to $4.3 million. Adjusted EBITDA improved over 440% to $2.5 million. SI-BONE ended the quarter with $144.7 million in cash. The company expanded its physician base 17% to over 1,650 active US physicians and launched products in Europe and Australia. CMS proposed creating a new payment category for complex spinal fusion procedures incorporating iFuse Bedrock Granite, potentially boosting hospital reimbursements.

PR Newswire
May 16th, 2024
Osteotec announces exclusive UK and Ireland distribution agreement with SI-BONE

NEWBURY, England, May 16, 2024 /PRNewswire/ - Osteotec, the market-leading manufacturer and distributor of medical devices, is pleased to announce a new partnership with SI-BONE to exclusively distribute the iFuse Implant System(R) in the UK and Ireland.

OrthospineNews
Jan 30th, 2024
SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application

The iFuse Bedrock Granite System was also awarded a Breakthrough Device Designation (BDD) by the Food & Drug Administration (FDA) and a New Technology Add-on Payment (NTAP) by the Centers for Medicare and Medicaid Services (CMS).